Clinical Trial

Routine Use of Potassium Competitive Acid Blocker vs. Guideline-Directed Gastrointestinal Protection Strategy in Acute Myocardial Infarction

Study acronym: PCAB-AMI
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
This study aims to compare the clinical outcomes between routine use of potassium competitive acid blocker (P-CAB) and guideline-directed gastrointestinal (GI) protection strategy in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI) and being treated with dual antiplatelet therapy (DAPT).
Protocol Amendment History 2 changes
critical Recruitment opened 2026-06-27
critical Phase changed: Phase 4 -> Phase 3 2026-06-27
Trial Details
NCT Number NCT07467213
Lead Sponsor Samsung Medical Center
Conditions Acute Myocardial Infarction (AMI), Gastrointestinal Bleeding
Enrollment 5,000 participants
Start Date 2026-06-23
Primary Completion 2029-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-06-26